Gene therapy aims to fix protein deficiency in lung and liver disease

NCT ID NCT07227207

Recruiting now Disease control Sponsor: Tessera Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 25, 2026 · Updated 22 times

Summary

This study tests an experimental gene therapy called TSRA-196 in 72 adults with a severe form of Alpha-1 Antitrypsin Deficiency (the PiZZ genotype) who have lung or liver disease. The treatment is designed to help the body produce more of the protective protein it lacks. The trial is in early phases (1 and 2) and focuses on safety, tolerability, and whether the therapy can raise protein levels to normal.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Study Center
RECRUITING

Boston, Massachusetts, 02118, United States
Clinical Study Center
RECRUITING

Charleston, South Carolina, 29425, United States
Clinical Study Center
RECRUITING

Fitzroy, Victoria, Australia

Conditions

Explore the condition pages connected to this study.

ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)